secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2026-09-29T20:19:02+00:00
Accession:  0001437749-26-031468
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Apyx Medical reports Renuvion study showing 30% elastin increase and 34% inflammation reduction at Day 180
--------------------------------------------------------------------------------

- Study published in Plastic and Reconstructive Surgery — Global Open evaluated Renuvion helium plasma RF on skin quality; n=6 completed Day 180.
- Treated tissue showed 30% increase in elastin fiber density and 55% increase in elastin staining intensity vs control.
- Treated tissue had 34% reduction in inflammation and 27% increase in elastin expression incidence vs untreated control.
- 100% of participants reported improvement, satisfaction, and would recommend; 100% showed physician- and patient-assessed aesthetic improvement.
- CEO Charlie Goodwin said findings support Renuvion's biological basis and that Renuvion should be part of every liposuction procedure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/0001437749-26-031468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000143774926031468/apyx20260929_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer